Bovalto Ibraxion

RSS
Withdrawn

This medicine's authorisation has been withdrawn

Infectious bovine rhinotracheitis vaccine (inactivated)
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Bovalto Ibraxion has been withdrawn at the request of the marketing authorisation holder.

български (BG) (273.86 KB - PDF)

View

español (ES) (211.53 KB - PDF)

View

čeština (CS) (261.66 KB - PDF)

View

dansk (DA) (213.32 KB - PDF)

View

Deutsch (DE) (220.08 KB - PDF)

View

eesti keel (ET) (204.87 KB - PDF)

View

ελληνικά (EL) (286.33 KB - PDF)

View

français (FR) (212.65 KB - PDF)

View

hrvatski (HR) (231.45 KB - PDF)

View

italiano (IT) (209.38 KB - PDF)

View

latviešu valoda (LV) (244.51 KB - PDF)

View

lietuvių kalba (LT) (233 KB - PDF)

View

magyar (HU) (249.94 KB - PDF)

View

Malti (MT) (258.21 KB - PDF)

View

Nederlands (NL) (211.02 KB - PDF)

View

polski (PL) (256.51 KB - PDF)

View

português (PT) (211.11 KB - PDF)

View

română (RO) (235.21 KB - PDF)

View

slovenčina (SK) (258.12 KB - PDF)

View

slovenščina (SL) (244.33 KB - PDF)

View

Suomi (FI) (209.31 KB - PDF)

View

svenska (SV) (209.74 KB - PDF)

View

Product information

български (BG) (705.71 KB - PDF)

View

español (ES) (674.36 KB - PDF)

View

čeština (CS) (969.79 KB - PDF)

View

dansk (DA) (624.29 KB - PDF)

View

Deutsch (DE) (661.81 KB - PDF)

View

eesti keel (ET) (692.55 KB - PDF)

View

ελληνικά (EL) (1.19 MB - PDF)

View

français (FR) (671.79 KB - PDF)

View

hrvatski (HR) (767.57 KB - PDF)

View

íslenska (IS) (680.52 KB - PDF)

View

italiano (IT) (679.81 KB - PDF)

View

latviešu valoda (LV) (999.57 KB - PDF)

View

lietuvių kalba (LT) (791.74 KB - PDF)

View

magyar (HU) (981.94 KB - PDF)

View

Malti (MT) (1007.77 KB - PDF)

View

Nederlands (NL) (671.31 KB - PDF)

View

norsk (NO) (684.14 KB - PDF)

View

polski (PL) (993.05 KB - PDF)

View

português (PT) (664.06 KB - PDF)

View

română (RO) (792.26 KB - PDF)

View

slovenčina (SK) (995.67 KB - PDF)

View

slovenščina (SL) (960.57 KB - PDF)

View

Suomi (FI) (678.92 KB - PDF)

View

svenska (SV) (676.34 KB - PDF)

View
Latest procedure affecting product information: IAIN/0016
10/08/2016

български (BG) (333.69 KB - PDF)

View

español (ES) (172.7 KB - PDF)

View

čeština (CS) (205.62 KB - PDF)

View

dansk (DA) (172.68 KB - PDF)

View

Deutsch (DE) (173.21 KB - PDF)

View

eesti keel (ET) (168.31 KB - PDF)

View

ελληνικά (EL) (215.76 KB - PDF)

View

français (FR) (171.23 KB - PDF)

View

hrvatski (HR) (192.67 KB - PDF)

View

íslenska (IS) (170.24 KB - PDF)

View

italiano (IT) (168.65 KB - PDF)

View

latviešu valoda (LV) (209.34 KB - PDF)

View

lietuvių kalba (LT) (200.78 KB - PDF)

View

magyar (HU) (191.94 KB - PDF)

View

Malti (MT) (214.75 KB - PDF)

View

Nederlands (NL) (170.59 KB - PDF)

View

norsk (NO) (168.61 KB - PDF)

View

polski (PL) (207.14 KB - PDF)

View

português (PT) (172.47 KB - PDF)

View

română (RO) (195.44 KB - PDF)

View

slovenčina (SK) (209.19 KB - PDF)

View

slovenščina (SL) (240.02 KB - PDF)

View

Suomi (FI) (166.83 KB - PDF)

View

svenska (SV) (172.67 KB - PDF)

View

Product details

Name of medicine
Bovalto Ibraxion
Active substance
inactivated IBR virus
International non-proprietary name (INN) or common name
Infectious bovine rhinotracheitis vaccine (inactivated)
Species
Cattle
Anatomical therapeutic chemical veterinary (ATCvet) code
QI02AA03

Pharmacotherapeutic group

Immunologicals for Bovidae

Therapeutic indication

Active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (IBR) and field virus excretion.
The onset of immunity is 14 days and the duration of immunity is 6 months.

Authorisation details

EMA product number
EMEA/V/C/000051
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
09/03/2000
Revision
10

Assessment history

This page was last updated on

Share this page